Amylyx Pharmaceuticals Q1 Earnings Call Highlights

2 hours ago 2

MarketBeat

Thu, May 7, 2026 astatine 8:22 AM CDT 8 min read

Amylyx Pharmaceuticals logo

Key Points

Avexitide Phase 3 LUCIDITY completed dosing and the institution says it’s connected way for a near-term top-line readout, with absorption and the CFO pointing to imaginable readout timing astir Q3 2026.
Expanded entree programme (EAP) launched successful the U.S. to supply avexitide to up to 250 adults with post‑bariatric hypoglycemia aft Roux‑en‑Y gastric bypass, intended to guarantee continuity of attraction for proceedings participants; the cause remains investigational.
Commercial and fiscal readiness: Amylyx is drafting NDA sections, gathering a motorboat enactment and disease‑awareness efforts targeting an estimated ~160,000 U.S. PBH patients, and ended Q1 with $279.8 million successful currency to money its runway into 2028 portion preparing for a imaginable 2027 motorboat if approved.
Interested successful Amylyx Pharmaceuticals, Inc.? Here are 5 stocks we similar better.

3 small-cap biotechs with imaginable breakthroughs successful 2024

Amylyx Pharmaceuticals (NASDAQ:AMLX) executives highlighted continued advancement crossed the company’s pipeline during its first-quarter 2026 net call, with a dense absorption connected the pivotal Phase 3 LUCIDITY proceedings evaluating avexitide successful post-bariatric hypoglycemia (PBH) and preparations for a imaginable 2027 commercialized motorboat if the cause is approved.

Avexitide Phase 3 LUCIDITY proceedings nearing top-line results

Co-CEO Justin Klee said the 4th was “marked by execution crossed our pipeline,” pointing archetypal to the LUCIDITY survey of avexitide, which the institution describes arsenic an investigational first-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy designation successful PBH. Klee said the institution randomized and dosed the past subordinate successful precocious March, calling it “a important milestone,” and said the institution remains “on way for a top-line readout adjacent quarter.”

→ The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches

These biotechs targeting aggregate neurodegenerative diseases

Chief Medical Officer Dr. Camille L. Bedrosian described PBH arsenic a chronic metabolic information driven by an exaggerated GLP-1 effect aft nutrient intake, starring to recurrent hypoglycemia and neuroglycopenia. She emphasized determination are presently nary FDA-approved therapies. Bedrosian said LUCIDITY is evaluating avexitide 90 mg erstwhile regular successful PBH pursuing Roux-en-Y gastric bypass surgery, utilizing an FDA-agreed superior endpoint: simplification successful the composite of level 2 and level 3 hypoglycemic events done week 16.

Bedrosian said LUCIDITY was designed with “the extremity of replication,” noting that 5 anterior avexitide trials successful PBH informed the dose, endpoint, and inclusion criteria. In Q&A, absorption said they mean to study further accusation beyond the superior endpoint, including secondary endpoints that look separately astatine level 2 and level 3 events. Bedrosian explained that level 3 events are adjudicated by an autarkic radical of endocrinologists blinded to survey data.

Read Entire Article